BioAge Labs(BIOA.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
BioAge Labs
BIOA.US
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults.
4.853 T
BIOA.USMarket value -Rank by Market Cap -/-

Financial Score

22/01/2026 Update
D
PharmaceuticalsIndustry
Industry Ranking134/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-25.64%E
    • Profit Margin-1280.90%E
    • Gross Margin-801.31%E
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-6.84%C
    • Total Assets YoY-9.57%E
    • Net Assets YoY-11.56%D
  • Cash ScoreD
    • Cash Flow Margin-7.81%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreA
    • Gearing Ratio9.06%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BioAge Announces Pricing of Upsized $115.0 Million Public Offering | BIOA Stock News

    BioAge Labs, Inc. has announced the pricing of its upsized public offering of 5,897,435 shares at $19.50 each, aiming to raise approximately $115 million. The offering is set to close around January 23, 2026, pending customary conditions. BioAge plans to use the proceeds for research, clinical development, and general corporate purposes. Goldman Sachs, Piper Sandler, and Citigroup are the joint book-running managers for the offering. This announcement follows the company's ongoing development of therapeutic candidates targeting metabolic diseases.

    StockTitan·
    US
    BIB
    +4.85%
    US
    BBH
    +3.20%
    US
    SBIO
    +1.94%
    StockTitan·
    US
    BIB
    +4.85%
    US
    BBH
    +3.20%
    US
    SBIO
    +1.94%

    BUZZ-BioAge dips after unveiling planned $75 mln stock sale

    BioAge Labsshares fell 2% premarket to $20.89 following a planned $75 million stock offering. The Emeryville, California-based biopharma company aims to use the proceeds for research and development of its product candidates, including BGE-102, a small-molecule NLRP3 inhibitor. Goldman Sachs, Piper Sandler, and Citigroup are the joint bookrunners. Despite the dip, BIOA shares have increased nearly 61% since the start of 2026, with one analyst rating it a "strong buy" and others giving hold ratings with price targets between $9-$15.

    Reuters·
    US
    XBI
    +2.31%
    US
    IBB
    +2.60%
    US
    IHE
    +1.46%
    Reuters·
    US
    XBI
    +2.31%
    US
    IBB
    +2.60%
    US
    IHE
    +1.46%

    BioAge Labs Proposes Public Offering Worth $75 Million

    BioAge Labs plans a public offering of up to $75 million in common shares, with underwriters having a 30-day option for an additional $11.3 million. The funds will support the advancement of product candidates, including BGE-102, debt reduction, and general corporate purposes. Following the announcement, shares fell over 5% in after-hours trading.

    fidelity·
    US
    ARKG
    +2.50%
    US
    FBT
    +3.38%
    US
    IHE
    +1.46%
    fidelity·
    US
    ARKG
    +2.50%
    US
    FBT
    +3.38%
    US
    IHE
    +1.46%

    BioAge Labs shares are trading lower after the company announced a $75 million stock offering.

    benzinga_article·
    US
    IBB
    +2.60%
    US
    BIOA
    -5.63%
    US
    FBT
    +3.38%
    benzinga_article·
    US
    IBB
    +2.60%
    US
    BIOA
    -5.63%
    US
    FBT
    +3.38%

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    In Tuesday's pre-market session, INVO Fertility (IVF) saw a significant gain of 345.6%, reaching $3.62, with a market cap of $12.2 million. Other notable gainers included RAPT Therapeutics (RAPT) up 63.78% to $57.49, and AlphaTON Capital (ATON) up 31.3% to $0.99. Conversely, Venus Concept (VERO) dropped 36.5% to $5.08, while Jaguar Health (JAGX) fell 32.26% to $0.97. Overall, several health care stocks experienced notable fluctuations in their pre-market prices.

    benzinga_article·
    US
    PBE
    +2.06%
    US
    IBB
    +2.60%
    US
    ARKG
    +2.50%
    benzinga_article·
    US
    PBE
    +2.06%
    US
    IBB
    +2.60%
    US
    ARKG
    +2.50%
    © 2026 Longbridge｜Disclaimer